Primary analysis of a prospective, randomized, single-blinded phase II trial evaluating the HER2 peptide AE37 vaccine in breast cancer patients to prevent recurrence von Mittendorf, E.A., Ardavanis, A., Symanowski, J., Murray, J.L., Shumway, N.M., Litton, J.K., Hale, D.F., Perez, S.A., Anastasopoulou, E.A., Pistamaltzian, N.F., Ponniah, S., Baxevanis, C.N., von Hofe, E., Papamichail, M., Peoples, G.E.

Volltext

Tumor-infiltrating and circulating granulocytic myeloid-derived suppressor cells correlate with disease activity and adverse clinical outcomes in mycosis fungoides von Argyropoulos, K. V., Pulitzer, M., Perez, S., Korkolopoulou, P., Angelopoulou, M., Baxevanis, C., Palomba, M. L., Siakantaris, M.

Volltext

Large-scale expansion of CD3+CD56+ lymphocytes capable of lysing autologous tumor cells with cytokine-rich supernatants von GRITZAPIS, A. D, DIMITROULOPOULOS, D, PARASKEVAS, E, BAXEVANIS, C. N, PAPAMICHAIL, M

Volltext

Natural killer lymphocytes: biology, development, and function von PAPAMICHAIL, Michael, PEREZ, Sonia A, GRITZAPIS, Angelos D, BAXEVANIS, Constantin N

Volltext

In Vivo Antitumor Activity of NKT Cells Activated by the Combination of IL-12 and IL-18 von Baxevanis, Constantin N, Gritzapis, Angelos D, Papamichail, Michael

Volltext

Peptide HER2(776–788) represents a naturally processed broad MHC class II-restricted T cell epitope von Sotiriadou, R, Perez, S A, Gritzapis, A D, Sotiropoulou, P A, Echner, H, Heinzel, S, Mamalaki, A, Pawelec, G, Voelter, W, Baxevanis, C N, Papamichail, M

Volltext

Cytokine serum levels, autologous mixed lymphocyte reaction and surface marker analysis in never medicated and chronically medicated schizophrenic patients von Theodoropoulou, St, Spanakos, G., Baxevanis, C.N., Economou, M., Gritzapis, A.D., Papamichail, M.P., Stefanis, C.N.

Volltext

Tumor-Specific CD4+ T Lymphocytes from Cancer Patients Are Required for Optimal Induction of Cytotoxic T Cells Against the Autologous Tumor von Baxevanis, Constantin N, Voutsas, Ioannis F, Tsitsilonis, Ourania E, Gritzapis, Angelos D, Sotiriadou, Roula, Papamichail, Michael

Volltext

An improved fluorescence assay for the determination of lymphocyte-mediated cytotoxicity using flow cytometry von Papadopoulos, Nikolaos G., Dedoussis, George V.Z., Spanakos, Gregory, Gritzapis, Angelos D., Baxevanis, Constantin N., Papamichail, Michael

Volltext

Cytotoxic T-cell precursor frequencies to HER-2 (369 – 377) in patients with HER-2/neu-positive epithelial tumours von Sotiropoulou, P A, Perez, S A, Iliopoulou, E G, Missitzis, I, Voelter, V, Echner, H, Baxevanis, C N, Papamichail, M

Volltext

Immunogenic HER-2/neu peptides as tumor vaccines von Baxevanis, Constantin N, Sotiriadou, Nectaria N, Gritzapis, Angelos D, Sotiropoulou, Panagiota A, Perez, Sonia A, Cacoullos, Nike T, Papamichail, Michael

Volltext

Pooled peptides from HER-2/neu-overexpressing primary ovarian tumours induce CTL with potent antitumour responses in vitro and in vivo von Gritzapis, A D, Perez, S A, Baxevanis, C N, Papamichail, M

Volltext

Immunobiology of HER-2/neu oncoprotein and its potential application in cancer immunotherapy von BAXEVANIS, Constantin N, SOTIROPOULOU, Panagiota A, SOTIRIADOU, Nectaria N, PAPAMICHAIL, Michael

Volltext

Targeting of tumor cells by lymphocytes engineered to express chimeric receptor genes von BAXEVANIS, Constantin N, PAPAMICHAIL, Michael

Volltext

Interactions Between Human Mesenchymal Stem Cells and Natural Killer Cells von Sotiropoulou, Panagiota A., Perez, Sonia A., Gritzapis, Angelos D., Baxevanis, Constantin N., Papamichail, Michael

Volltext

Redirecting mouse T hybridoma against human breast and ovarian carcinomas: in vivo activity against HER-2/neu expressing cancer cells von Gritzapis, A D, Mamalaki, A, Kretsovali, A, Papamatheakis, J, Belimezi, M, Perez, S A, Baxevanis, C N, Papamichail, M

Volltext

Tumor specific cytolysis by tumor infiltrating lymphocytes in breast cancer von Baxevanis, Constantin N., Dedoussis, George V. Z., Papadopoulos, Nikolaos G., Missitzis, Ioannis, Stathopoulos, George P., Papamichail, Michael

Volltext

POD-04.04: Phase I Clinical Study of the Novel LI-Key/HER-2(776-790) Hybrid Peptide Vaccine in Patients with Prostate Cancer von Bisias, S, Georgakopoulou, K, Rempelakos, A, Koutsiaris, E, Papas, A, Arvanitakis, T, Kalinteris, N, Von Hofe, E, Baxevanis, C, Thanos, A

Volltext

Elevated prostaglandin E2 production by monocytes is responsible for the depressed levels of natural killer and lymphokine‐activated killer cell function in patients with breast ca... von Baxevanis, Constantin N., Reclos, George J., Gritzapis, Angelos D., Dedousis, George V. Z., Missitzis, Ioannis, Papamichail, Michael

Volltext

Compromised anti‐tumor responses in tumor necrosis factor‐α knockout mice von Baxevanis, Constantin N., Voutsas, Ioannis F., Tsitsilonis, Ourania E., Tsiatas, Marinos L., Gritzapis, Angelos D., Papamichail, Michael

Volltext